Windtree Therapeutics (NASDAQ:WINT) Shares Set to Reverse Split on Monday, April 22nd

Shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) are going to reverse split on Monday, April 22nd. The 1-18 reverse split was announced on Monday, April 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, April 22nd.

Windtree Therapeutics Price Performance

Shares of NASDAQ WINT traded down $0.06 during mid-day trading on Thursday, reaching $0.34. The company had a trading volume of 1,789,008 shares, compared to its average volume of 280,849. The company has a 50-day moving average price of $0.37 and a two-hundred day moving average price of $0.67. The stock has a market cap of $1.75 million, a PE ratio of -0.04 and a beta of 0.61. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 2.00. Windtree Therapeutics has a 1-year low of $0.27 and a 1-year high of $7.79.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of Windtree Therapeutics in a research note on Wednesday, January 3rd.

Institutional Investors Weigh In On Windtree Therapeutics

Large investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in Windtree Therapeutics during the 4th quarter worth approximately $28,000. Citadel Advisors LLC purchased a new position in shares of Windtree Therapeutics during the fourth quarter valued at $27,000. Vanguard Group Inc. acquired a new position in Windtree Therapeutics during the third quarter valued at $40,000. Envestnet Asset Management Inc. lifted its stake in Windtree Therapeutics by 97.8% in the 4th quarter. Envestnet Asset Management Inc. now owns 212,236 shares of the company’s stock worth $36,000 after acquiring an additional 104,934 shares in the last quarter. Finally, Millennium Management LLC boosted its position in Windtree Therapeutics by 411.1% during the 2nd quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after acquiring an additional 64,232 shares during the period. Institutional investors and hedge funds own 29.33% of the company’s stock.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.